Design of experiment mediated development of stability indicating high performance thin layer chromatography method invoking failure mode effect analysis based risk assessment in estimation of edoxaban tosylate monohydrate
By: Mistry, Vrunda Balvantbhai
.
Contributor(s): Patel, Hitika Bharatbhai.
Publisher: Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022Edition: Vol.56(2), Apr-June.Description: 553-563p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical education and researchSummary: Aim: Development of stability indicating high performance thin layer chromatographic
method for quantification of edoxaban tosylate monohydrate in its pharmaceutical
dosage form using quality by design approach. Methods: Degradation was performed
in acidic, alkaline, neutral, oxidative and photolytic conditions. Analytical target profile
was identified, based on which failure modes were identified by brainstorming session
and preliminary trials. Each failure mode was assigned a risk priority number based on
its severity and detectability. Identified potential method variables were further screened
by Taguchi OA design. 32 full factorial design was applied for optimization of critical
factors. The developed analytical method was validated using the Q2R1 guideline of
the International Council for Harmonization. Results: In acidic, alkaline, and oxidative
environments, the substance was shown to be degraded. After failure mode analysis,
seven factors were found potential for estimation as it shows high risk priority number
(RPN). Two important method variables, the volume of modifier and migration distance,
were screened using screening design from these seven components. For the estimation
of edoxaban tosylate monohydrate, the response surface model created design space
and a control strategy was devised. Method found to be accurate, precise, and linear,
with detection limit 1.021 ng/band and quantification limit 3.095 ng/band. Conclusion:
Using methanol-ethyl acetate-triethylamine (6:4:0.2, v/v) as mobile phase on silica gel
GF254 plate, described method was effectively employed for estimation of edoxaban
tosylate monohydrate in its tablet dosage form.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-1448 |
Aim: Development of stability indicating high performance thin layer chromatographic
method for quantification of edoxaban tosylate monohydrate in its pharmaceutical
dosage form using quality by design approach. Methods: Degradation was performed
in acidic, alkaline, neutral, oxidative and photolytic conditions. Analytical target profile
was identified, based on which failure modes were identified by brainstorming session
and preliminary trials. Each failure mode was assigned a risk priority number based on
its severity and detectability. Identified potential method variables were further screened
by Taguchi OA design. 32 full factorial design was applied for optimization of critical
factors. The developed analytical method was validated using the Q2R1 guideline of
the International Council for Harmonization. Results: In acidic, alkaline, and oxidative
environments, the substance was shown to be degraded. After failure mode analysis,
seven factors were found potential for estimation as it shows high risk priority number
(RPN). Two important method variables, the volume of modifier and migration distance,
were screened using screening design from these seven components. For the estimation
of edoxaban tosylate monohydrate, the response surface model created design space
and a control strategy was devised. Method found to be accurate, precise, and linear,
with detection limit 1.021 ng/band and quantification limit 3.095 ng/band. Conclusion:
Using methanol-ethyl acetate-triethylamine (6:4:0.2, v/v) as mobile phase on silica gel
GF254 plate, described method was effectively employed for estimation of edoxaban
tosylate monohydrate in its tablet dosage form.
Click on an image to view it in the image viewer
There are no comments for this item.